AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 5.5% year on year to $695.4 million. On the other hand, the company’s full-year revenue guidance of $3.05 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $0.21 per share was 43.2% above analysts’ consensus estimates.

Is now the time to buy AMRX? Find out in our full research report (it’s free).

StockStory’s Take

Amneal’s first quarter was shaped by steady revenue growth across its core generics and branded specialty segments, with management crediting robust uptake of the Parkinson’s drug CREXONT and expansion in injectables for the period’s performance. The company continued to benefit from a diverse portfolio, new product launches, and a growing U.S. manufacturing footprint, while leadership cited operational efficiency initiatives and favorable product mix as factors behind the improvement in margins. Co-CEO Chirag Patel highlighted, “We are embarking on our next phase of growth with momentum and confidence in our ability to deliver on our goals in 2025 and beyond.”

Looking ahead, Amneal’s management remains focused on execution across multiple growth drivers, including the scaling of its biosimilars business and the anticipated launch of additional specialty products. The company reaffirmed its full-year guidance, pointing to upcoming milestones in its injectable and biosimilar portfolios, the expansion of GLP-1 manufacturing capabilities, and further market access for CREXONT. Management stated that ongoing investments in digitization and automation support its long-term strategy of becoming a leading supplier of affordable medicines.

Key Insights from Management’s Remarks

Amneal’s leadership attributed the quarter’s outcome to portfolio breadth, successful new launches, and efficiency gains. Revenue missed Wall Street’s expectations, but adjusted profit and margins exceeded consensus due to product mix and cost controls.

• CREXONT launch momentum: CREXONT, Amneal’s branded Parkinson’s medication, continued to exceed early expectations, with rapid market share gains and expanded insurance coverage from 30% to 60% of U.S. covered lives in six months. Management cited strong patient and provider feedback and expects CREXONT to reach peak sales between $300 million and $500 million.
• Injectables and new launches: The affordable medicines segment grew through a mix of complex generic and injectable product launches. The company introduced BORUZU, its fourth 505(b)(2) injectable in a year, highlighting a strategic emphasis on hospital-ready formulations that improve efficiency and reimbursement for providers.
• Biosimilars as a growth vector: Amneal’s first three biosimilars generated $125 million in revenue in the last year. Five additional biosimilar regulatory filings are planned for this year, with a goal of vertical integration to capture more value and address a market where many biologic drugs are losing exclusivity.
• U.S. manufacturing as a differentiator: Leadership underscored Amneal’s large U.S. manufacturing footprint, producing two-thirds of its medicines domestically. This provides supply chain resilience and a potential advantage if tariffs on imported pharmaceuticals increase.
• GLP-1 partnership and facility buildout: The partnership with Metsera positions Amneal as a supplier and commercial partner for next-generation weight loss (GLP-1) therapies. Construction of new peptide and oral fill-finish facilities is underway, aiming to support future supply and contract manufacturing opportunities.

Drivers of Future Performance

Management’s outlook for the coming quarters is anchored in the expansion of its specialty and biosimilar portfolios, operational leverage, and continued investment in manufacturing capacity, with a focus on mitigating external risks such as tariffs.

• Specialty and biosimilars expansion: Growth is expected from additional launches in the specialty segment—including the DHE autoinjector for migraines—and the scaling of biosimilar offerings, which management believes will drive both revenue and margin improvement.
• Operational efficiency initiatives: Investments in automation, digitization, and supply chain optimization are expected to enhance margins and support cost containment, even as the company ramps up new product introductions.
• Tariff and regulatory risk management: The company’s U.S. manufacturing base and proactive inventory and sourcing strategies are intended to limit the impact of potential tariffs or regulatory delays, though management noted that economic viability and customer acceptance of any cost increases remain important variables.

Top Analyst Questions

• David Amsellem (Piper Sandler): Asked for details on biosimilar revenue contribution and vertical integration timing; leadership confirmed a $150–$160 million target for biosimilars this year and expects vertical integration options to be finalized by early next year.
• David Amsellem (Piper Sandler): Inquired about the focus between complex and shortage-driven injectables; management stated they are prioritizing both equally, with ongoing launches in each area and infrastructure to support growth.
• Les Sulewski (Truist Securities): Queried about AvKARE’s exposure to federal cuts; management responded federal cuts do not apply to pharmaceuticals and sees ongoing volume growth in government channels.
• Les Sulewski (Truist Securities): Asked about FDA approval timelines and CREXONT’s ex-U.S. expansion; management reported no FDA delays and outlined ongoing partnerships for CREXONT in Europe, Latin America, and Asia.
• Chris Schott (JPMorgan): Requested insight on leverage of U.S. manufacturing in the event of tariffs; management highlighted available capacity and willingness to increase domestic production if economically justified, with discussions ongoing with major customers about sharing potential cost increases.

Catalysts in Upcoming Quarters

In the quarters ahead, the StockStory team will be monitoring (1) the commercial uptake and payer coverage expansion of CREXONT and upcoming specialty launches, (2) progress on biosimilar regulatory filings and the pace of vertical integration, and (3) operational milestones related to new manufacturing facility buildouts and the GLP-1 partnership with Metsera. Sustained margin improvement and execution on complex injectable launches will also be key indicators of strategic progress.

Amneal currently trades at a forward P/E ratio of 10.7×. In the wake of earnings, is it a buy or sell? Find out in our free research report.

The Best Stocks for High-Quality Investors

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.